AA
NVLN

Apriem Advisors’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Apriem Advisors’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-205
Closed -$2K – 615
2017
Q1 		$2K Hold
205
– – ﹤0.01% 610
2016
Q4 		$2K Buy
+205
New +$1.82K ﹤0.01% 646

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Apriem Advisors's NVLN Position: Q2 2017 in Review

Apriem Advisors sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2017, closing a stake of 205 shares — an estimated $2K sold.

Apriem Advisors first reported a position in NVLN in Q4 2016 and held it in 2 quarters. The position peaked at $2K in Q1 2017. 76 funds tracked by Wall St. Rank hold NVLN as of Q2 2017.

  • Apriem Advisors reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2017 after selling out during the quarter.
  • Apriem Advisors sold 205 Novelion Therapeutics Inc. Common Shares shares in Q2 2017, an estimated $2K.
  • Apriem Advisors first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 2 quarters.
  • Apriem Advisors's Novelion Therapeutics Inc. Common Shares position peaked at $2K in Q1 2017.
  • 76 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2017.

Based on Apriem Advisors's 13F filing for Q2 2017, filed 4 Aug 2017.